Press Releases
  Date Title View
Nov 14, 2016
- Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores - - Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models - SAN DIEGO , Nov. 14, 2016 (GLOBE NEWSWIRE...
Nov 9, 2016
SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Stifel 2016 Healthcare Conference in New York at 8:45 a.m. ET on Wednesday, November 16, 2016. An au...
Nov 8, 2016
SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2016, and provided updates on its clini...
Nov 3, 2016
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH for Portal Hypertension), a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the company's first-in-class, orally-active pan-caspase inhibitor, in a...
Nov 1, 2016
SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the third quarter ended September 30, 2016, after the market clos...
Oct 3, 2016
Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models SAN DIEGO, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Con...
Aug 3, 2016
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2016, and provided updates on its clinical de...
Jul 27, 2016
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2016, after the market close on W...
Jun 14, 2016
SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meeting...
May 5, 2016
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs...
FirstPrevious
3
...
NextLast
= add release to Briefcase